Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Paul GermonpréTim Van den WyngaertPublished in: PloS one (2019)
Second-line erlotinib after pemetrexed treatment results in similar real-world outcomes as reported after non-pemetrexed containing first-line therapy. However, the overall duration of response in unselected patients remains limited and other effective treatments have in the meantime been introduced. No new safety signals were detected.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- systematic review
- tyrosine kinase
- prognostic factors
- open label
- type diabetes
- squamous cell carcinoma
- metabolic syndrome
- radiation therapy
- patient reported outcomes
- study protocol
- combination therapy
- smoking cessation
- insulin resistance
- double blind